Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
59 participants
OBSERVATIONAL
2022-07-05
2025-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Single Use ERCP Performance -SURE Study
NCT04671095
A Single-Use Duodenoscope in a Real-World Setting
NCT04628949
The Development and Evaluation of a Novel Duodenoscope Assessment Tool
NCT04004533
Early Versus Late Laparoscopic Exploration of Common Bile Duct After Failure of Extraction of Common Bile Duct Stones by ERCP
NCT05823181
Failed Retrograde Cholangiopancreatography (ERCP) Stone Extraction: Surgical Interference
NCT05746832
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Gall stones are made of cholesterol, pigment and mixture of cholesterol and pigment. The incidence of stones with in the bile-duct varies from 4.6% to 19%.The stones are predominantly formed in the gall bladder and are displaced from the gall bladder in to the bile duct via the cystic duct. ERCP is an effective and minimally invasive treatment for bile duct stones. Treatment of extrahepatic biliary strictures; irrespective of their aetiology, is to place a stent across the stricture through ERCP and facilitate biliary drainage.
There is emerging data that the incidence of carbapenem resistant enterobacteriae, Multidrug-resistant Klebsiella pneumoniae, and New Delhi metallo-β-lactamase-producing carbapenem-resistant Escherichia coli (CRE) following exposure to contaminated duodenoscopes (ERCP endoscopes). The main reason for the outbreaks is due to inadequate reprocessing (Cleaning of endoscope post procedure) leading to contamination of endoscopes. To minimize the risk of contamination and outbreak of above infections, single use disposable duodenoscopes have been brought in to the market. The aim of the study is to assess the performance of the single use duodenoscope and the cost consequences associated with the above.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients who Undergo ERCP procedure with aScope
This will be patients who undergo ERCP procedure using aScope.
Endoscopic retrograde Cholangio-pancreatography (ERCP) with aScope (Single use duodenoscope
ERCP Procedure will be done using aScope. We will assess the performance of the aScope.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endoscopic retrograde Cholangio-pancreatography (ERCP) with aScope (Single use duodenoscope
ERCP Procedure will be done using aScope. We will assess the performance of the aScope.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Jaundice (Bilirubin \>21)
* Primary sclerosing cholangitis
* Post liver transplant anastomotic stricture
* Inpatients
* Combined procedures (Ex: ERCP+ spy glass cholangioscopy)
* Previous inadequate biliary drainage.
* Biliary stricture
* Participant is willing and able to give informed consent for participation in the study.
* Male or Female, aged 18 years or above.
* Grade 1-3 ERCP on complexity grading (ASGE grading)
* Able (in the Investigators opinion) and willing to comply with all study requirements.
* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.
Exclusion Criteria
* Sphincter of Oddi manometry.
* Female participants who is pregnant, lactating or planning pregnancy during the course of the study.
* Patients who are unable to consent for the study.
* ERCP for Pancreatic pathology.
* Grade 4 complex ERCP (ASGE grading)
* Participant who is terminally ill /ECOG 4
* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nottingham University Hospitals NHS Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Suresh V Venkatachalapathy, MRCP
Role: STUDY_CHAIR
Nottingham University Hospitals NHS Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nottingham University Hospitals NHS Trust
Nottingham, Nottingham, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21GA088
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.